News & Updates
Filter by Specialty:
Levonorgestrel-releasing intrauterine system reduces pelvic pain but may increase expulsion risk
In the treatment of patients with organic disease and heavy menstrual bleeding and/or dysmenorrhea, the use of levonorgestrel-releasing intrauterine system (LNG-IUS) attenuates chronic pelvic pain, according to a study. However, it appears to confer an increased risk of expulsion for some women.
Levonorgestrel-releasing intrauterine system reduces pelvic pain but may increase expulsion risk
06 Sep 2022Brolucizumab noninferior to aflibercept in nAMD
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022Liraglutide boosts lipid metabolism in T2DM, but comes with more side effects
Compared with dapagliflozin, the glucagon-like peptide 1 liraglutide induces better lipid metabolism in patients with type 2 diabetes mellitus (T2DM), a recent study has found. However, this drug also comes with more adverse events than its sodium-glucose co-transporter 2 inhibitor comparator.